Intravenous glycyrrhizin for the treatment of chronic hepatitis C: A double‐blind, randomized, placebo‐controlled phase I/II trial

Abstract

Glycyrrhizin up to 240 mg, thrice weekly, lowers serum ALT during treatment, but has no effect on HCV-RNA levels. The drug appears to be safe and is well tolerated. In view of the reported long-term effect of glycyrrhizin, further controlled investigation of the Japanese mode of administration (six times weekly) for induction appears of interest.